Clarity Pharmaceuticals (ASX:CU6) Total Stockholders Equity: A$232.81 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:CU6 Clarity Pharmaceuticals Ltd ASX:CU6
33 GF Score
Price A$2.10
! 2 Warning Signs
View Full Analysis

What is Clarity Pharmaceuticals Total Stockholders Equity?

Clarity Pharmaceuticals ASX:CU6 +0.48% 33 Total Stockholders Equity is A$232.81 Mil as of Dec. 2025. GuruFocus rates ASX:CU6 with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

Clarity Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2025 was A$232.81 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Clarity Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2025 was A$0.63. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Clarity Pharmaceuticals's Debt-to-Equity for the quarter that ended in Dec. 2025 was 0.00.

Clarity Pharmaceuticals  (ASX:CU6) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Clarity Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(232.814-0)/372.030
=0.63

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Clarity Pharmaceuticals's Debt-to-Equity for the quarter that ended in Dec. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 232.814
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clarity Pharmaceuticals Total Stockholders Equity Related Terms

Clarity Pharmaceuticals Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Clarity Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clarity Pharmaceuticals Total Stockholders Equity Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Total Stockholders Equity
92.24 69.18 146.30 90.23

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only 53.06 146.30 127.35 90.23 232.81
ASX:CU6
33GF Score
Clarity Pharmaceuticals Ltd ASX:CU6
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of A$232.81 Mil mean?
Clarity Pharmaceuticals (ASX:CU6) has a Total Stockholders Equity of A$232.81 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Clarity Pharmaceuticals and its competitors.
Is Clarity Pharmaceuticals' Total Stockholders Equity too high?
Clarity Pharmaceuticals' current Total Stockholders Equity is A$232.81 Mil. Overall, Clarity Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Clarity Pharmaceuticals' Total Stockholders Equity compare to VRTX and REGN?
Clarity Pharmaceuticals' Total Stockholders Equity of A$232.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Clarity Pharmaceuticals and its competitors. Clarity Pharmaceuticals's current Total Stockholders Equity is A$232.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clarity Pharmaceuticals stock overvalued right now?
Clarity Pharmaceuticals (ASX:CU6) has a current Total Stockholders Equity of A$232.81 Mil. The current Total Stockholders Equity is A$232.81 Mil. Clarity Pharmaceuticals' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Clarity Pharmaceuticals (ASX:CU6), the current Total Stockholders Equity is A$232.81 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clarity Pharmaceuticals Business Description

Other Exchanges CLRPF:USA1F4:Germany
Address 2-4 Cornwallis Street, Suite 212a, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
33GF Score

Get the complete analysis for ASX:CU6

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.10
Price